INTRODUCTION: Patients may fail oral overactive bladder therapies due to either poor drug efficacy or intolerability. We determined if the success of sacral neuromodulation varies if performed secondary to lack of anticholinergic efficacy versus drug intolerability. METHODS: A retrospective review was performed on 152 patients undergoing staged sacral neuromodulation from 2004 to 2010 for refractory idiopathic detrusor overactivity with or without urge incontinence. Outcomes following sacral neuromodulation trials were compared based on the primary indication for anticholinergic failure: lack of drug efficacy versus intolerable side effects. RESULTS: Overall, successful sacral neuromodulation trials were reported in 70% (106/152) of patients. Successful outcomes were noted in 70% (89/128) and 71% (17/24) of patients with poor anti-cholinergic efficacy and drug intolerability, respectively (p = NS). CONCLUSIONS: We found no significant difference in outcome success in patients undergoing sacral neuromodulation trials for refractory detrusor overactivity due to lack of anticholinergic efficacy versus intolerability.
INTRODUCTION:Patients may fail oral overactive bladder therapies due to either poor drug efficacy or intolerability. We determined if the success of sacral neuromodulation varies if performed secondary to lack of anticholinergic efficacy versus drug intolerability. METHODS: A retrospective review was performed on 152 patients undergoing staged sacral neuromodulation from 2004 to 2010 for refractory idiopathic detrusor overactivity with or without urge incontinence. Outcomes following sacral neuromodulation trials were compared based on the primary indication for anticholinergic failure: lack of drug efficacy versus intolerable side effects. RESULTS: Overall, successful sacral neuromodulation trials were reported in 70% (106/152) of patients. Successful outcomes were noted in 70% (89/128) and 71% (17/24) of patients with poor anti-cholinergic efficacy and drug intolerability, respectively (p = NS). CONCLUSIONS: We found no significant difference in outcome success in patients undergoing sacral neuromodulation trials for refractory detrusor overactivity due to lack of anticholinergic efficacy versus intolerability.
Authors: Anco C Van Voskuilen; Dennis J A J Oerlemans; Ernest H J Weil; Ubi van den Hombergh; Philip E V A van Kerrebroeck Journal: BJU Int Date: 2006-09-06 Impact factor: 5.588
Authors: Wesley M White; Joe D Mobley; Regula Doggweiler; Cindy Dobmeyer-Dittrich; Frederick A Klein Journal: J Urol Date: 2009-08-15 Impact factor: 7.450
Authors: Joshua S Benner; Michael B Nichol; Eric S Rovner; Zhanna Jumadilova; Jose Alvir; Mohamed Hussein; Kristina Fanning; Jeffrey N Trocio; Linda Brubaker Journal: BJU Int Date: 2009-11-12 Impact factor: 5.588
Authors: Asha E Jamzadeh; Donghua Xie; Melissa Laudano; Stephan Seklehner; Dean S Elterman; Lucien Shtromvaser; Richard Lee; Steven A Kaplan; Alexis E Te; Bilal Chughtai Journal: World J Urol Date: 2013-07-25 Impact factor: 4.226